Swiss National Bank acquired a new stake in CytomX Therapeutics, Inc. (NASDAQ:CTMX – Free Report) during the first quarter, according to its most recent 13F filing with the SEC. The fund acquired 319,600 shares of the biotechnology company’s stock, valued at approximately $1,502,000. Swiss National Bank owned 0.19% of CytomX Therapeutics as of its most recent filing with the SEC.
Other institutional investors have also added to or reduced their stakes in the company. HB Wealth Management LLC lifted its holdings in CytomX Therapeutics by 100.0% during the first quarter. HB Wealth Management LLC now owns 50,000 shares of the biotechnology company’s stock valued at $235,000 after purchasing an additional 25,000 shares during the last quarter. Y Intercept Hong Kong Ltd purchased a new position in shares of CytomX Therapeutics in the first quarter worth about $787,000. Pictet Asset Management Holding SA purchased a new position in shares of CytomX Therapeutics in the first quarter worth about $78,000. Cannon Global Investment Management LLC bought a new stake in shares of CytomX Therapeutics in the first quarter valued at approximately $452,000. Finally, Hsbc Holdings PLC bought a new stake in shares of CytomX Therapeutics in the fourth quarter valued at approximately $52,000. 67.77% of the stock is owned by hedge funds and other institutional investors.
CytomX Therapeutics Stock Down 5.5%
Shares of CTMX opened at $3.10 on Friday. The business’s 50-day moving average price is $3.39 and its 200-day moving average price is $4.31. CytomX Therapeutics, Inc. has a twelve month low of $1.72 and a twelve month high of $8.21. The stock has a market cap of $527.59 million, a PE ratio of -7.56 and a beta of 2.08.
Wall Street Analyst Weigh In
A number of analysts recently commented on CTMX shares. Weiss Ratings restated a “sell (d)” rating on shares of CytomX Therapeutics in a research note on Tuesday, June 16th. Wall Street Zen upgraded shares of CytomX Therapeutics from a “strong sell” rating to a “sell” rating in a research note on Saturday, May 9th. Wolfe Research initiated coverage on shares of CytomX Therapeutics in a report on Tuesday, May 19th. They set an “outperform” rating and a $6.00 target price on the stock. Zacks Research upgraded CytomX Therapeutics from a “hold” rating to a “strong-buy” rating in a research report on Tuesday, July 21st. Finally, HC Wainwright cut their price target on CytomX Therapeutics from $17.00 to $11.00 and set a “buy” rating for the company in a report on Monday, May 11th. Two investment analysts have rated the stock with a Strong Buy rating, nine have given a Buy rating and one has given a Sell rating to the company’s stock. According to MarketBeat, the company presently has a consensus rating of “Buy” and an average target price of $12.10.
View Our Latest Research Report on CTMX
About CytomX Therapeutics
CytomX Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on the discovery and development of next-generation therapeutics based on its proprietary Probody® platform. The company engineers masked antibody prodrugs that remain inactive in healthy tissue but are selectively activated in the tumor microenvironment. This approach is designed to enhance the safety and tolerability of antibody-based therapies, particularly those targeting immuno-oncology pathways.
At the core of CytomX’s pipeline is Pacmilimab (CX-072), an anti–PD-L1 Probody therapeutic currently undergoing clinical evaluation for multiple solid tumor indications.
Featured Stories
- Five stocks we like better than CytomX Therapeutics
- Chevron’s Strong Quarter Shows Why It Still Leads the Energy Sector
- Amazon’s Earnings Beat Shows Why AWS Is Back at the Center of the Bull Case
- Apple’s Record Quarter Could Not Outrun Its Guidance Problem
- McKesson’s Compounding Keeps Adding Up
Receive News & Ratings for CytomX Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CytomX Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
